Intervention

Propranolol

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 20 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials20

Recruiting1

Common conditions25

Lead sponsors shown15

Clinical trials

20 shown

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast CancerNCT05741164 · 2024-09-01

Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic VaricesNCT07352228 · 2026-01-01

ENROLLING_BY_INVITATION

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · 2024-02-16

ACTIVE_NOT_RECRUITING

Perioperative Propranolol During Prostatectomy to Decrease Cancer RecurrenceNCT05679193 · 2023-01-02

Carvedilol vs. Propranolol in Second Prophylaxis of Variceal BleedingNCT05651789 · 2023-01-01

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/SertralineNCT05189977 · 2022-09-07

Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal HypertensionNCT03720067 · 2019-01-25

HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803)NCT03783065 · 2019-01-02

The Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric VaricesNCT03171805 · 2017-06-01

8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A CirrhosisNCT03094234 · 2017-04-28

8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal RebleedingNCT02477384 · 2015-06-01

Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockersNCT02104011 · 2015-05-22

The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal BleedingNCT02385422 · 2015-03-01

Bevacizumab vs Dacarbazine in Metastatic MelanomaNCT01705392 · 2013-01-01

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant ChemotherapyNCT01847001 · 2012-10-01

Beta Blocker Therapy in Mild to Moderate AsthmaticsNCT01544634 · 2012-04-04

Propranolol for Diabetic RetinopathyNCT01535495 · 2012-02-01

Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal VaricesNCT01970748 · 2009-08-01

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management StrategyNCT00935805 · 2006-07-01

Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)NCT01000779 · 2005-01-01

Common conditions

Leading sponsors

West China Hospital 4 Columbia University 1 Emory University 1 Govind Ballabh Pant Hospital 1 Haukeland University Hospital 1 Hospital de Clinicas de Porto Alegre 1 Janssen Research & Development, LLC 1 Nanfang Hospital, Southern Medical University 1 Oslo University Hospital 1 Otsuka Pharmaceutical Development & Commercialization, Inc. 1 Shanghai Zhongshan Hospital 1 Taipei Veterans General Hospital, Taiwan 1 Universidade Federal do Rio de Janeiro 1 University Hospital, Bordeaux 1 University of Dundee 1

Trial status mix

UNKNOWN8

COMPLETED6

TERMINATED3

ACTIVE_NOT_RECRUITING1

ENROLLING_BY_INVITATION1

RECRUITING1

Phase mix

PHASE28

NA5

PHASE43

PHASE12

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.